Cite
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.
MLA
Perdrix, Anne, et al. “PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type P53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.” Cancers, vol. 9, no. 12, Dec. 2017, p. 172. EBSCOhost, https://doi.org/10.3390/cancers9120172.
APA
Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017). PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. Cancers, 9(12), 172. https://doi.org/10.3390/cancers9120172
Chicago
Perdrix, Anne, Ahmad Najem, Sven Saussez, Ahmad Awada, Fabrice Journe, Ghanem Ghanem, and Mohammad Krayem. 2017. “PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type P53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.” Cancers 9 (12): 172. doi:10.3390/cancers9120172.